COVID-19, vaccination against SARS-CoV-2 and antiviral treatment in rheumatic diseases - revised opinion of the Czech Society for Rheumatology
Authors:
Šenolt Ladislav; Kolektiv Výboru České Revmatologické Společnosti
Authors place of work:
Revmatologický ústav Praha
Published in the journal:
Čes. Revmatol., 30, 2022, No. 1, p. 9-18.
Category:
Recomendation
Summary
COVID-19 is an acute respiratory disease caused by a new type of coronavirus SARS-CoV-2, which can be asymptomatic or life-threatening with multiorgan failure. Patients with systemic and inflammatory rheumatic diseases generally have an increased risk of infectious complications, which is influenced not only by the severity of the immune-related disease but also by specific immunomodulatory and immunosuppressive treatments. As the number of new findings increases exponentially in the context of SARS-CoV-2 infection, some of which are contradictory, the Czech Society for Rheumatology (ČRS) decided to update the original opinion on COVID-19 in rheumatic diseases based on recent literature as well as international scientific recommendations. The risk of infection and the prognosis of COVID-19 in rheumatic patients, the effect of antirheumatic treatment on the course of COVID-19, the latest findings on the efficacy and safety of vaccination against SARS-CoV-2, including an updated opinion on vaccination timing and specific treatment in individuals with immune-mediated rheumatic diseases. Finally, the indication of antiviral treatment to high-risk rheumatic patients is also discussed.
Keywords:
infections – vaccination – glucocorticoids – SARS-CoV-2 – COVID-19 – disease-modifying treatment – inflammatory and systemic rheumatic diseases
Zdroje
1. Šenolt L. a kolektiv Výboru České Revmatologické Společnosti. Stanovisko České revmatologické společnosti k léčbě revmatických onemocnění a očkování v kontextu infekce SARS-CoV-2. Čes. Revmatol. 2020; 28(4): 197–205.
2. Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79(7): 851–858.
3. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version2. Arthritis Rheumatol 2020; 72(9): e1–e11.
4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52(1): 53–61.
5. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2020; annrheumdis-2020-218946.
6. Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared
with the general population: a systematic review and meta-analysis. Rheumatol Int 2021; 41(5): 851–861.
7. Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS--CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic
and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis 2022; 81(3): 422–432.
8. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9(6): 622–42.
9. Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory
rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford) 2021; 60(SI): SI59–SI67.
10. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with
rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; 80(4): 527–538.
11. Bower H, Frisell T, Di Giuseppe D, et al; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 2021; 80(8): 1086–1093.
12. Strangfeld A, Schäfer M, Gianfrancesco MA, et al; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician–reported registry. Ann Rheum Dis 2021; 80(7): 930–942.
13. D’Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared
to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol 2021; 73(6): 914–920.
14. Rutter M, Lanyon PC, Grainge MJ, et al. COVID-19 infection, admission and death amongst people with rare autoimmune rheumatic
disease in England. Results from the RECORDER project. Rheumatology (Oxford) 2021: keab794.
15. Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti--inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul 2021; 81: 100818.
16. Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021; 3(10): e724– e736.
17. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory
rheumatic diseases treated with rituximab. Ann Rheum Dis 2021; 80(5): e67.
18. Sparks JA, Wallace ZS, Seet AM, et al; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic
or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the covid-19 Global Rheumatology
Alliance physician registry. Ann Rheum Dis 2021; 80(9): 1137–1146.
19. Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14(3): 898–907.
20. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20(4): 102792.
21. Tang KT, Hsu BC, Chen DY. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol 202112; 12: 645013.
22. Foret T, Dufrost V, Salomon Du Mont L, et al. Systematic review of antiphospholipid antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep 2021; 23(8): 65.
23. Schenker HM, Hagen M, Simon D, Schett G, Manger B. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. Rheumatology (Oxford) 20215; 60(1): 479–480.
24. Zacharias H, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of Covid 19. Autoimmun Rev 2021; 20(9): 102883.
25. Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021; 40(7): 2611–2619.
26. Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges forp healthcare professionals. Arch Med Res 2021; 52(6): 575–581.
27. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28: 583–590.
28. Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol 2021: https://doi.org/10.1007/s12016-021-08848-3
29. Metyas S, Chen C, Aung T, Ballester A, Cheav S. Rheumatologic manifestations of post SARS-CoV-2 infection: a Case Series. Curr Rheumatol Rev 2022; doi: 10.2174/1573397118666220211155 716
30. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20(11): e276–e288.
31. Ruddy JA, Connolly CM, Boyarsky BJ, et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80(10): 1351–1352.
32. Seror R, Camus M, Salmon JH, et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIKSFR Registry. Lancet Rheumatol 2022; 4(1): e8–e11.
33. Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 2021; 3(11): e778– e788.
34. Sieiro Santos C, Calleja Antolin S, Moriano Morales C, et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open 2022; 8(1): e001898. 3
5. Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021; 80(10): 1322–1329.
36. Krasselt M, Wagner U, Nguyen P, et al. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford) 2022: keac089.
37. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician–reported registry. Ann Rheum Dis 2021; annrheumdis-2021-221490.
38. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA 2022; 327(7): 639–651.
39. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence – 25 U.S. Jurisdictions, April 4 – December 25, 2021. MMWR Morb Mortal Wkly Rep 2022; 71(4): 132–138.
40. Barbhaiya M, Levine JM, Bykerk VP, Jannat–Khah D, Mandl LA. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis 2021; 80(10): 1352–1354.
41. Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 2022; 24(1): 21.
42. Connolly CM, Ruddy JA, Boyarsky BJ, et al. Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 2022; 74(1): 28–32.
43. https://www.rheumatology.org/Portals/0/Files/covid-19-Vaccine- Clinical-Guidance-Rheumatic-Diseases-Summary.pdf
44. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARSCoV- 2: the November 2021 update. Ann Rheum Dis 2022; annrheumdis- 2021-222006.
45. Bijlsma JW; EULAR COVID-19 Task Force. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis 2022; annrheumdis-2021-221965.
46. Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7(1): e001464.
47. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022; 19: 1–6. https:// doi.org/10.1038/s41591-021-01678-y
48. van de Veerdonk FL, Giamarellos–Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med 2022; 28(1): 39–50.
49. Borio LL, Bright RA, Emanuel EJ. A national strategy for COVID-19 medical countermeasures: Vaccines and therapeutics. JAMA 2022; 327(3): 215–216.
50. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest 2020; 130(12): 6409–6416.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2022 Číslo 1
Najčítanejšie v tomto čísle
- Education of patients with rheumatic diseases using methotrexate – a manual for nurses
- COVID-19, vaccination against SARS-CoV-2 and antiviral treatment in rheumatic diseases - revised opinion of the Czech Society for Rheumatology
- MUDr. Karel Pavelka, CSc.
- Achieving the goal of rheumatoid arthritis treatment is more common in patients with moderate activity than high disease activity in the real clinical practice of the ATTRA National Registry of Biological Treatment